COPENHAGEN, Denmark, April 2, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that JYNNEOS®, the only FDA-approved mpox vaccine, is now commercially available in the U.S., marking a significant expansion for access to JYNNEOS® by establishing additional pathways for vaccine procurement, distribution, and reimbursement by both public and private payers.
Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.
The two-week ceasefire agreed upon on Tuesday between the USA, Israel, and Iran marks the preliminary end of an escalation that has gripped the Middle East since February 2026.
A winter storm with up to 15 centimeters of new snow has plunged Germany into traffic chaos. Highways and country roads are blocked in many places, accidents are increasing, and the…
Dementia is a progressive brain disease that leads to a decline in cognitive abilities. It affects memory, thinking, orientation, and the…
